Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab before surgery (neoadjuvant) then with radiotherapy (with or without cisplatin) after surgery (adjuvant) for untreated, resectable, locally advanced, squamous cell head and neck cancer.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6477
Provisional Schedule
- Expected publication:
- 05 August 2026
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email [email protected]
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 24 July 2025 - 07 August 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 24 July 2025 | In progress. Scoping commenced. |
| 12 December 2024 | Referral |
| 19 August 2024 | Topic selection |
| 16 July 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual